Vikneswari Rajasegaran
Overview
Explore the profile of Vikneswari Rajasegaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2020
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guan P, Chen J, Mo C, Fukawa T, Zhang C, Cai X, et al.
EMBO Mol Med
. 2024 Aug;
16(9):2132-2145.
PMID: 39122888
Collecting duct carcinoma (CDC) is an aggressive rare subtype of kidney cancer with unmet clinical needs. Little is known about its underlying molecular alterations and etiology, primarily due to its...
2.
Tan Q, Shannon N, Lim W, Teo J, Yap D, Lek S, et al.
Front Oncol
. 2024 Jun;
14:1272432.
PMID: 38939336
Introduction: Field cancerization is suggested to arise from imbalanced differentiation in individual basal progenitor cells leading to clonal expansion of mutant cells that eventually replace the epithelium, although without evidence....
3.
Ng C, Lim S, Lim A, Nasir N, Zhang J, Rajasegaran V, et al.
Front Mol Biosci
. 2022 Oct;
9:963243.
PMID: 36213130
A well-validated diagnostic assay with curated biomarkers complements clinicopathological factors to facilitate early diagnosis and ensure timely treatment delivery. This study focuses on an Asian-centric cancer diagnostic assay designed and...
4.
Lee L, Sim A, Ong C, Yang X, Ng C, Liu W, et al.
Prostate Cancer Prostatic Dis
. 2022 Mar;
25(4):803.
PMID: 35288663
No abstract available.
5.
Lee L, Sim A, Ong C, Yang X, Ng C, Liu W, et al.
Prostate Cancer Prostatic Dis
. 2022 Jan;
25(4):741-748.
PMID: 35091711
Objective: Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II investigation of neoadjuvant...
6.
Ng C, Nasir N, Loke B, Tay T, Thike A, Rajasegaran V, et al.
Mod Pathol
. 2021 Mar;
34(7):1320-1332.
PMID: 33727697
Breast fibroepithelial lesions are biphasic tumors which comprise the common benign fibroadenomas (FAs) and the rarer phyllodes tumors (PTs). This study analyzed 262 (42%) conventional FAs, 45 (7%) cellular FAs,...
7.
Lim J, Huang D, Tang T, Tan D, Laurensia Y, Peng R, et al.
Leukemia
. 2021 Mar;
35(4):1225.
PMID: 33686199
No abstract available.
8.
Tan G, Goh S, Lim A, Liu W, Lee J, Rajasegaran V, et al.
Cancer Sci
. 2020 Nov;
112(1):397-409.
PMID: 33164299
Giant cells (GC) are a poorly understood subset of tumor cells that have been increasingly recognized as a potential contributor to tumor heterogeneity and treatment resistance. We aimed to characterize...
9.
Lim J, Huang D, Tang T, Tan D, Laurensia Y, Peng R, et al.
Leukemia
. 2020 Aug;
34(12):3413-3419.
PMID: 32753688
No abstract available.
10.
Tan B, Nasir N, Chang H, Ng C, Guan P, Nagarajan S, et al.
Mod Pathol
. 2020 Apr;
33(9):1732-1745.
PMID: 32322022
Breast fibroepithelial lesions (FELs) encompass the common fibroadenoma (FA) and relatively rare phyllodes tumour (PT); the latter entity is usually classified as benign, borderline or malignant. Intratumoural heterogeneity is frequently...